Neuregulin 4
| Neuregulin 4 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||
| Symbols | NRG4 ; HRG4 | ||||||||||||
| External IDs | OMIM: 610894 MGI: 1933833 HomoloGene: 12921 GeneCards: NRG4 Gene | ||||||||||||
| |||||||||||||
| Orthologs | |||||||||||||
| Species | Human | Mouse | |||||||||||
| Entrez | 145957 | 83961 | |||||||||||
| Ensembl | ENSG00000169752 | ENSMUSG00000032311 | |||||||||||
| UniProt | Q8WWG1 | Q9WTX4 | |||||||||||
| RefSeq (mRNA) | NM_138573 | NM_032002 | |||||||||||
| RefSeq (protein) | NP_612640 | NP_114391 | |||||||||||
| Location (UCSC) |
Chr 15: 75.94 – 76.06 Mb |
Chr 9: 55.22 – 55.33 Mb | |||||||||||
| PubMed search | |||||||||||||
Neuregulin 4 also known as NRG4 is a member of the neuregulin protein family which in humans is encoded by the NRG4 gene.[1][2][3]
Function
The neuregulins, including NRG4, activate type-1 growth factor receptors (EGFR) to initiating cell-to-cell signaling through tyrosine phosphorylation.[3]
Clinical significance
Loss of expression of NRG4 is frequently seen in advanced bladder cancer while increased NRG4 expression correlates to better survival.[4]
References
- ↑ "Entrez Gene: NRG4 neuregulin 4".
- ↑ Strausberg RL, Feingold EA, Grouse LH, et al. (December 2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC: 139241. PMID 12477932.
- 1 2 Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y (April 1999). "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase". Oncogene 18 (17): 2681–9. doi:10.1038/sj.onc.1202631. PMID 10348342.
- ↑ Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, Nexo E (December 2004). "Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients". Br. J. Cancer 91 (12): 2034–41. doi:10.1038/sj.bjc.6602251. PMC: 2409781. PMID 15583696.
Further reading
- Révillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP (January 2008). "ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis". Ann. Oncol. 19 (1): 73–80. doi:10.1093/annonc/mdm431. PMID 17962208.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC: 528928. PMID 15489334.
- Hayes NV, Newsam RJ, Baines AJ, Gullick WJ (2008). "Characterization of the cell membrane-associated products of the Neuregulin 4 gene.". Oncogene 27 (5): 715–20. doi:10.1038/sj.onc.1210689. PMID 17684490.
- Hayes NV, Blackburn E, Smart LV, et al. (2007). "Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer.". Clin. Cancer Res. 13 (11): 3147–55. doi:10.1158/1078-0432.CCR-06-2237. PMID 17545517.
| ||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.